Rs9561778

From SNPedia
Jump to: navigation, search

Orientationplus
Geno Mag Summary
(G;G) 1 Normal risk of adverse drug reations from cyclophosphamide treatments
(G;T) 1.5 ~2x increased risk of adverse drug reactions from cyclophosphamide treatments
(T;T) 1.5 ~2x increased risk of adverse drug reactions from cyclophosphamide treatments
ReferenceGRCh38 38.1/141
Chromosome13
Position95061461
GeneABCC4
is asnp
is mentioned by
dbSNPrs9561778
Exacrs9561778
PheGenIrs9561778
nextbiors9561778
hapmaprs9561778
1000 genomesrs9561778
hgdprs9561778
ensemblrs9561778
gopubmedrs9561778
geneviewrs9561778
scholarrs9561778
googlers9561778
pharmgkbrs9561778
gwascentralrs9561778
openSNPrs9561778
23andMers9561778
23andMe allrs9561778
SNP Nexus

SNPshotrs9561778
SNPdbers9561778
MSV3drs9561778
GMAF0.1837
? (G;G) (G;T) (T;T) 28
rs9561778 is a SNP in the ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 gene.

A stepwise case-control study of ~400 breast cancer Japanese patients receiving cyclophosphamide-based combination chemotherapy, roughly divided equally between those having or not having serious adverse drug reactions (ADRs), concluded that carriers of rs9561778(T) allele had a ~2x higher risk of ADRs. The ADRs for these patients tended to be gastrointestinal toxicity and leukopenia/neutropenia.[PMID 19696793]



GET Evidence
rs9561778
aa_change
aa_change_short
impact pharmacogenetic
qualified_impact Insufficiently evaluated pharmacogenetic
overall_frequency 0.117188
summary